We'd like to offer you the job cheap medication Lazaridis, who now controls 8 percent of the company, hasengaged Goldman Sachs and Centerview Partners LLC to assist witha strategic review of his stake. He held almost 5.7 percent asof the end of 2012, according to Thomson Reuters data.